PDGFRB and systemic sclerosis: The B-cell depleting drug Rituximab, which may have beneficial effects on lung function and skin fibrosis in SSc patients [3], has been associated with reduced PDGFR phosphorylation in SSc skin [3], supporting the possibility of agonistic anti-PDGFR-autoantibodies.